Effects of Shenkang injection combined with Febuxostat in treatment of gouty nephropathy complicated with chronic renal failure
Objective:To observe effects of Shenkang injection combined with Febuxostat in treatment of patients with gouty nephropathy(GN)complicated with chronic renal failure(CRF).Methods:The clinical data of 134 patients with GN complicated with CRF admitted to this hospital from May 2021 to May 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,67 cases in each group.The control group was treated with Febuxostat,while the observation group was treated with Shenkang injection on the basis of that of the control group.The clinical efficacy,the renal function indexes[glomerular filtration rate(eGFR),serum creatinine(Scr),blood urea nitrogen(BUN)]levels,the oxidative stress indexes[superoxide dismutase(SOD),myeloperoxidase(MPO),malondialdehyde(MDA)]levels,the renal fibrosis indexes[fibroblast growth factor 2(FGF2),bone morphogenetic protein-7(BMP-7),connective tissue growth factor(CTGF)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 91.04% (61/67),which was higher than 77.61% (52/67)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of eGFR,SOD,BMP-7 in the observation group were higher than those in the control group,the levels of Scr,BUN,MPO,MDA,FGF2,and CTGF were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Shenkang injection combined with Febuxostat in the treatment of the GN complicated with CRF can improve the total effective rate of treatment,and improve the levels of renal function indexes,oxidative stress indexes and renal fibrosis indexes.Moreover,it is superior to single Febuxostat treatment.
万方数据
维普
